Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- SABCS 2018: Recommendations From Dr. Lee Schwartzberg
- Molecular Profiling
- Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual HER2 Blockade for HER2-Positive Breast Cancer
- Prolonged PFS With Atezolizumab + nab-Paclitaxel in Advanced TNBC
- Growth Factors and Febrile Neutropenia
- Pathological Response and Survival in TNBC After Neoadjuvant Carboplatin + Docetaxel
- PARP Inhibitors and Carboplatin for Neoadjuvant Triple Negative Breast Cancer Treatment—A West Cancer Center Perspective
- Long-Term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy in Metastatic Triple-Negative Breast Cancer
- Talazoparib in Patients With Advanced Breast Cancer and a Germline BRCA Mutation
- Psychosocial Outcomes of Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer